Spain · AEMPS CIMA

FLUENZ SUSPENSION PARA PULVERIZACION NASAL

A source-listed medicine record.

Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.

Medicine identity

Source reference
1241816001
Form
SUSPENSIÓN PARA PULVERIZACIÓN NASAL
Composition / generic term
vacuna anti gripal
Source strength
7 ± 0,5 log10
Authorisation holder
Astrazeneca Ab
Marketed in source snapshot
Yes

Source-listed ingredients

  • VIRUS INFLUENZA GRIPE, REASORTANTE, VIVO ATENUADO, CEPA SIMILAR A A/ MISSOURI/11/2025 (H1N1) PDM09 — 7,0 ± 0,5 FFU
  • VIRUS INFLUENZA GRIPE, REASORTANTE, VIVO ATENUADO CEPA SIMILAR A A/DARWIN/1454/2025 (H3N2), (A/DARWIN/1369/2025, MEDI 406666) — 7,0 ± 0,5 FFU
  • VIRUS INFLUENZA GRIPE REASORTANTE,VIVO, ATENUADO, CEPA SIMILAR A B/ TOKYO/EIS13-175/2025 — 7,0 ± 0,5 FFU

These values do not establish equivalence or a dose recommendation.

Packages

  • FLUENZ SUSPENSION PARA PULVERIZACION NASAL, 1 aplicador nasal
  • FLUENZ SUSPENSION PARA PULVERIZACION NASAL, 10 aplicadores nasales

Source and coverage

Open AEMPS CIMA →

Snapshot retrieved: 2026-09-18. This is the acquisition date, not a medical review date.

Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.

Browse Spain records →